Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ASP Isotopes (ASPI) Accused of Deceiving Investors with Bogus Nuclear Tech Claims - Hagens Berman

ASPI

ASPI Investors with Losses Encouraged to Contact the Firm

SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2024 / ASP Isotopes Inc. (NASDAQ:ASPI) and certain of its most senior executives are now entangled in a securities class action, alleging the company deceived investors by making false and misleading statements about its advanced nuclear fuel technologies.

Hagens Berman urges investors in ASP Isotopes who suffered substantial losses to submit your losses now.

Class Period: Oct. 30, 2024 - Nov. 26, 2024

Lead Plaintiff Deadline: Feb. 3, 2025

Visit: www.hbsslaw.com/investor-fraud/aspi

Contact the Firm Now: ASPI@hbsslaw.com

844-916-0895

ASP Isotopes Inc. (ASPI) Securities Class Action:

The suit, filed in the United States District Court for the Southern District of New York, claims that ASPI misled investors about the viability and potential of its Aerodynamic Separation Process (ASP) and Quantum Enrichment technologies.

The complaint alleges that ASPI overstated the effectiveness of its enrichment technologies, the development potential of its high assay low-enriched uranium facility, and the performance of its nuclear fuels operating segment.

The truth emerged on Nov. 26, 2024, when a scathing report by Fuzzy Panda Research revealed that ASPI's technology was outdated and unlikely to be commercially viable.

The report accused ASPI of using "old, disregarded laser enrichment technology" to falsely position itself as a cutting-edge nuclear fuel company. It also alleged that ASPI had employed individuals to promote its stock and that former executives of Centrus Energy had deemed its technology "virtually worthless.".

Following the release of the report, ASPI's stock price plummeted 23% in a single trading day.

These events have prompted shareholder rights firm Hagens Berman to open a probe.

"We are investigating whether ASPI may have misled investors about the true commercial prospects for its ASP and Quantum Enrichment technologies," said Reed Kathrein, a partner leading the investigation.

If you invested in ASP Isotopes or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the ASP Isotopes case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding ASP Isotopes should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ASPI@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP



View the original press release on accesswire.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today